Skip to main
ENGN

ENGN Stock Forecast & Price Target

ENGN Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 17%
Buy 67%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

The positive outlook for enGene Holdings Inc. is largely driven by the strong clinical results of detalimogene, which show a six-month complete response (CR) rate that meets the standards of leading competitors while benefiting from a non-viral delivery system. The recent protocol amendments have significantly improved CR rates, aligning them with the best-in-class assets, thereby enhancing investor expectations and confidence in the product's market potential. Moreover, the company has adjusted its discounted cash flow (DCF)-derived price target upward, indicative of increased conviction in the projected sales, which are anticipated to reach $530 million by 2031.

Bears say

The financial outlook for enGene Holdings Inc is negatively impacted by several key factors. First, the disappointment in Detalimogene's performance during the LEGEND trial, indicated by lower complete response (CR) rates compared to earlier data, raises concerns about the viability of achieving regulatory approval, which is further complicated by changing regulatory requirements and unforeseen competition from more established companies in the biotechnology field. Additionally, the company is likely facing higher-than-expected capital requirements, leading to an anticipation of equity dilution, which could diminish shareholder value and adversely affect its ability to fund ongoing drug development.

ENGN has been analyzed by 6 analysts, with a consensus rating of Buy. 17% of analysts recommend a Strong Buy, 67% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Engene Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Engene Holdings Inc (ENGN) Forecast

Analysts have given ENGN a Buy based on their latest research and market trends.

According to 6 analysts, ENGN has a Buy consensus rating as of Mar 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Engene Holdings Inc (ENGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.